Kymera Therapeutics held its Q2 call. No new data. KT-474 Phase 2 readout reaffirmed for H2 2026. Cash funds into 2028. Next catalyst: KT-474.
Kymera Therapeutics held its second-quarter 2026 earnings call on Aug. 5, with CEO Nello Mainolfi, CFO Bruce Jacobs, and new chief medical officer Terence Rooney taking questions from analysts at a dozen firms.
No new clinical data were released. Mainolfi walked through progress on the company's protein degrader platform, focusing on KT-474, an IRAK4 degrader for hidradenitis suppurativa and atopic dermatitis. Management reaffirmed plans to report Phase 2 data for the asset in the second half of 2026.
Jacobs said revenue from the Sanofi collaboration and the company's cash position fund operations into 2028. R&D spending ticked up as the pipeline advanced. The net loss landed in line with prior quarters.
Mainolfi also discussed KT-333, a STAT3 degrader in solid tumors, and KT-253, an MDM2 degrader. No new guidance on dose-escalation timelines or potential partnership announcements emerged. Analysts pressed on competitive positioning for KT-474 against other therapies in HS and AD, and on the likelihood of new collaborations. Management did not offer specifics.
The call left investors with a clear picture of Kymera's near-term pipeline. The next catalyst is the KT-474 Phase 2 readout, expected before year-end.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.